<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00397098</url>
  </required_header>
  <id_info>
    <org_study_id>LTE5894</org_study_id>
    <secondary_id>EudraCT 2006-002253-71</secondary_id>
    <nct_id>NCT00397098</nct_id>
  </id_info>
  <brief_title>Prevention of Relapse Study of SR58611A in Improved Patients With Generalized Anxiety Disorder</brief_title>
  <acronym>VEGA</acronym>
  <official_title>A Double-Blind Randomized Withdrawal Study Evaluating the Efficacy and Safety of SR58611A Versus Placebo in the Prevention of Relapse of Anxiety up to 1 Year in Patients With GAD Improved After 12 Weeks of Open Label Treatment With SR58611A.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy and safety of SR58611A (350 mg BID)
      compared to placebo in the prevention of relapse of anxiety, in patients with Generalized
      Anxiety Disorder improved after 12 weeks of treatment with SR58611A.

      The primary objective is to evaluate the efficacy of SR58611A 350mg BID compared to placebo
      over a 24 to 52-week treatment period.

      The secondary objective is to assess the safety and tolerability of SR58611A in patients with
      GAD.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    reprioritization of indications
  </why_stopped>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary criterion is the time to relapse of anxious symptoms (in days) from randomization date defined by either:</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>HAM-A total score â‰¥ 15 confirmed at a subsequent visit 2 weeks later unless the patient drops out,or</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Any drop-out for lack of efficacy (according to investigator's decision),or</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Prescription/use of alternative or additional treatments for relief of psychiatric symptoms.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline (V7) in:-Clinical Global Impression (CGI) Severity of Illness Score</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hamilton Anxiety Rating Scale (HAM-A)</measure>
  </secondary_outcome>
  <enrollment type="Actual">257</enrollment>
  <condition>Anxiety Disorders</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SR58611A</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        For entry into the open phase:

          -  Patients suffering from generalized anxiety disorder, according to Diagnostic and
             Statistical Manual of Mental Disorders (DSM-IV-TR) criteria and assessed with the Mini
             International Neuropsychiatric Interview (MINI) plus Generalized Anxiety Disorder
             (GAD) module.

          -  With a total score on the 14-item Hamilton Anxiety Rating Scale (HAM-A) &gt; 20 at
             V1(D-4) and V2 (D-1).

        For entry into the double-blind randomized phase:

          -  Improved patients with HAM-A score &lt; 11 at V7 (W12).

        Exclusion Criteria:

          -  Inpatients.

          -  Patients with a diagnosis of Major Depressive Disorder (DSM IV-TR) within 6 months of
             screening.

          -  Patients with a MADRS total score &gt; 18 at screening or baseline.

          -  Patients at immediate risk for suicidal behaviour.

          -  Patients with other current (within 6 months) anxiety disorder according to the MINI

          -  Patients with a lifetime history according to the MINI of: Bipolar disorder, Psychotic
             disorder, Antisocial personality disorder.

          -  Patients with a current history according to the MINI of: Anorexia nervosa or bulimia
             nervosa in the past 6 months, Alcohol or substance dependence or abuse in the past 12
             months, except nicotine or caffeine dependence.

        The investigator will evaluate whether there are other reasons why a patient may not
        participate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ICD CSD</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Macquarie Park</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Chile</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Russian Federation</country>
    <country>Spain</country>
  </location_countries>
  <removed_countries>
    <country>South Africa</country>
  </removed_countries>
  <link>
    <url>http://www.sanofi-aventis.com</url>
  </link>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 7, 2006</study_first_submitted>
  <study_first_submitted_qc>November 7, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 8, 2006</study_first_posted>
  <last_update_submitted>March 10, 2009</last_update_submitted>
  <last_update_submitted_qc>March 10, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 12, 2009</last_update_posted>
  <responsible_party>
    <name_title>ICD Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <keyword>Anxiety disorders, Relapse prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anxiety Disorders</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amibegron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

